Search Results

Pulse Biosciences, Inc., a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ technology, announced enhancements to its executive leadership team to support its next pivotal phase of growth.

Pulse Biosciences, Inc. today announced that it has commenced its previously announced rights offering of up to $60,000,000 of units (the “Units,” and each, a “Unit”) at the Initial Price (as defined below).

Pulse Biosciences, Inc., a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ technology, announced that its Board of Directors has unanimously approved plans to initiate a rights offering.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2024.

Pulse Biosciences, Inc. today announced CellFX nsPFA technology will be featured in multiple presentations at the upcoming Heart Rhythm Society (HRS) 2024 Annual Meeting in Boston, MA from May 16-19.

Pulse Biosciences, Inc. today announced the first procedure with the CellFX nsPFA Percutaneous Electrode System in the United States has been completed.

Pulse Biosciences, Inc., a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ technology, announced that the Company’s Board of Directors has determined a new record date for the Company’s previously announced rights offering, which will be available to all holders of record of the Company’s common stock, par value $0.001 per share, now as of the close of the market on Friday, May 31, 2024.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024.